top of page

A Family Owned Investment Holding Company That Fosters Projects For The Future 

Now open to co-investment opportunities


Biotech | Digitech | Medtech | Fintech

Welcome to Kinled, a forward-thinking family office which retains the assets held by the esteemed Anglo-Austrian Aisher Family through direct investments in defensible ventures emerging from Life Science and Digital Technology sectors.

Our Story

In 1924, the Aisher family founded Marley, which they developed into a group of innovative manufacturing and retail businesses in the concrete building materials, plastics, automotive components, and retail industries. 

Over 75 years, the family expanded the business to incorporate more than 13,000 workers in 59 countries. 

Following Sir Owen Aisher’s death, the family and Kinled Holding Limited sold their participation when the company was acquired for $600M in 1999

Owen Aisher Sr

At the time the company was founded – 1924

Kinled made additional investments in the 1970s, including shareholdings in General Shale, one of the largest brick manufacturers in the United States, which was acquired by Wienerberger in 1999 for $260M, and MDL Marinas, today Europe’s largest marina group, which was sold onto the London Stock Exchange in 1985.

Over the past 30 years, Patrick Aisher has built a portfolio of over 150 Direct investments, had over 50 successful exits (including 20 via IPO) and co-invested alongside renouned VC firms and Family offices.

Company President Sir Owen Aisher & Chairman Dr. Jack Aisher

Celebrating the company's 50th Anniversary – 1974

Patrick Aisher

Celebrating 25 years as Chairman – 2022


Now open to co-investment opportunities

• ETH Zürich • Bern • Fribourg • Geneva • Lausanne

• Vienna • Innsbruck • Graz

• Boston • Cambridge • Harvard • Houston • MIT • Michigan • New York • Northeastern • San Diego • San Francisco • Stanford

In Europe, Kinled portfolio firms were created with technology from universities such as Aix-Marseille, Amsterdam, Barcelona, Helsinki, Linköping, London, Paris, Pecs, and Utrecht.

How We Invest

Kinled Holding and the Aisher Family have long believed in fostering academic projects to become fully-fledged commercial businesses.

We are exceptionally proud to have funded early-stage businesses from some of the most prestigious universities in the world, including:

  • We are committed to championing innovation within the BioTech industry, including bio-pharmaceuticals, which, alongside MedTech, collectively constitute more than 50% of our portfolio.

    Key Holdings Include:

  • Our unwavering dedication to Life Sciences includes the dynamic landscape of the MedTech industry, where we’ve invested in medical devices and healthcare services sectors. Combined with BioTech, this constitutes over 50% of our portfolio. 

    Key Holdings Include:

  • In digital technologies, we invest in SaaS-enabled networks and marketplaces, where technology can democratise markets and provide consumers with a greater choice of services.

    Key Holdings Include:

  • In FinTech, we invest in companies that use technology to challenge the traditionally established institutions by providing superior service in embedded payment platforms, insurance, real estate, lending and banking.